Obesity drug sibutramine has had its licence suspended following safety fears over increased cardiovascular events.Pharmacists should stop dispensing the medicine immediately and advise patients to contact their doctor to consider alternatives, the MHRA said.There are no health implications if patients stop treatment before visiting their GP.The decision to suspend marketing authorisation for sibutramine, brand name Reductil, follows evidence of an increased risk of non-fatal cardiovascular events in patients taking the drug, the MHRA said.The drug has been suspended across Europe.